introduction to uk go data gprd: general practice research database thin: health improvement network...
Post on 21-Dec-2015
217 views
TRANSCRIPT
![Page 1: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/1.jpg)
Introduction to UK GO data
GPRD: General Practice Research Database
THIN: Health Improvement Network
Some new data too
![Page 2: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/2.jpg)
Data sources
• Records from GP routine records • GPRD=THIN (almost)• >6% of the UK population• >350 GP practices• >6½ million individual people
![Page 3: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/3.jpg)
UK NHS―National Health Service
• Largest UK employer―4th largest employer in world• 1.7 million employees• 40,000 GPs• 10,000 GP practices• GPs see 140 patients per week
![Page 4: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/4.jpg)
Data content
• Diagnoses: GP and some hospital• Biochemistry: HbA1c etc• Risk factors: weight, smoking etc• Family history (some)• Drugs (all prescribed drugs)• Outpatient contacts • Free text• GPRD only….linked data:
• Cancer registry data• Hospital inpatient data
![Page 5: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/5.jpg)
Quality: representativeness
The Population of the United Kingdom (2001) Compared to the Population of THIN
0
2
4
6
8
10
12
14
16
18
0-4 5-14 15-24 25-34 35-44 45-54 55-64 65-74 75-84 85+
Age Groups Years
Po
pu
lati
on
in
%
Population of UK Population of THIN
![Page 6: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/6.jpg)
Quality: completeness
THIN Data - Recording Over Time in adults
0
10
20
30
40
50
60
70
80
90
100
Year
Pati
en
ts (
%)
Smoking
Height
Weight
BP
![Page 7: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/7.jpg)
Quality: completeness
0.000%
0.200%
0.400%
0.600%
0.800%
1.000%
1.200%
Geographical region
% d
eath
*
% death in THIN
% death in UK
![Page 8: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/8.jpg)
Strengths
• Size―over 5% UK population• Nationally representative• Fast―information already collected • Frequent collections• All prescribable drugs• Population based• Study design flexibility • ‘Real Life’ data―collected during normal GP visit• Link to GP and patient for additional information
![Page 9: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/9.jpg)
Weaknesses
• £cost! • No direct link to secondary care data (THIN)• No direct link of prescriptions to diagnoses -
temporal implied link• Limited information on OTC medications• Limited data on lifestyles, diet etc• Not dispensed prescriptions• Limited information on hospital prescribing• Some medications only administered by specialists
![Page 10: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/10.jpg)
Weaknesses re Ca.
• Details of the cancer diagnosis variable • No systematic cancer staging data• Metastatic cancer: have to infer• Hospital cancer treatments not known
![Page 11: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/11.jpg)
New data!
Survival after incident cancer: diabetes vs. non-diabetes
![Page 12: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/12.jpg)
Incident cancers by cancer site
All cancers Breast Prostate Colorectal Lung Bladder Ovary and
Endometrium Pancreas Liver Parameter NDM DM NDM DM NDM DM NDM DM NDM DM NDM DM NDM DM NDM DM NDM DM Patients – n; % 140,141 9,890
30,901 1,286
16,872 1,475
15,617 1,363
12,666 891
7,076 716
5,625 424
2,125 375
1,334 252
Age – years (mean) 65.7 71.4
58.8 70.0
72.1 73.6
69.6 72.1
70.1 72.1
70.7 72.4
63.6 67.5
70.8 71.2
68.8 69.8 Sex – % women 53.3 41.0
99.0 97.7
n/a n/a
46.9 39.0
38.6 36.1
27.7 18.8
100.0 100.0
53.8 44.5
47.9 29.8
Smoking – % ever smoked 42.4 52.1
33.1 35.8
44.3 52.1
39.2 49.1
68.5 78.0
52.2 62.7
27.6 31.0
41.4 56.0
43.6 60.7 Diabetes duration – years (mean) n/a 10.4
n/a 11.3
n/a 11.0
n/a 11.2
n/a 8.6
n/a 11.4
n/a 10.4
n/a 5.6
n/a 9.0
BMI males – kg/m2 (mean) 26.0 28.6
25.7 27.8
26.1 28.3
26.3 29.0
25.1 28.4
26.1 28.7
n/a n/a
25.8 28.2
26.5 29.4 BMI females – kg/m2 (mean) 25.8 30.4
25.7 30.7
n/a n/a
25.8 29.5
24.9 29.2
25.8 28.7
27.3 32.7
25.5 28.3
26.2 31.0
SBP – mmHg (mean) 139.5 139.0
138.3 141.8
141.4 140.0
139.3 137.4
138.3 135.3
142.3 140.9
140.6 141.1
140.1 135.3
137.9 136.2 Total cholesterol – mmol/l (mean) 5.0 4.4
5.5 4.8
4.9 4.3
4.9 4.3
4.8 4.2
4.9 4.5
5.5 4.7
5.1 4.4
5.0 4.3
HbA1c in year prior – % 5.8 7.4
5.9 7.5
5.8 7.3
5.8 7.3
6.2 7.5
6.1 7.5
5.8 7.4
6.2 8.5
5.7 7.3 Prior vascular disease – %
Large vessel disease 13.9 30.7
6.1 23.3
19.9 34.3
15.4 30.4
21.5 40.3
19.9 34.6
8.2 20.0
16.2 25.9
17.6 32.9 Eye problems (some) 1.3 14.4
0.9 13.8
1.5 14.5
1.6 16.3
1.5 14.0
1.7 12.4
1.0 12.0
1.8 11.2
1.7 20.2
Eye problems (severe visual loss/blindness) 1.8 3.3
1.1 3.1
1.9 3.0
2.2 3.4
2.4 4.0
2.2 2.1
1.4 3.3
2.6 2.4
2.6 3.2
No renal disease 99.1 92.9
99.7 95.6
98.6 91.1
99.2 93.1
99.1 91.0
98.4 92.2
99.4 94.8
99.1 95.2
99.1 94.8 Mild renal disease 0.0 4.6
0.0 2.8
0.0 5.7
0.0 4.2
0.0 7.0
0.0 5.3
0.0 3.5
0.0 3.0
0.1 2.8
Moderate/severe renal disease 0.9 2.5
0.3 1.5
1.4 3.2
0.7 2.7
0.9 2.0
1.6 2.5
0.6 1.6
0.9 1.8
0.8 2.4 General morbidity:
Charlson index, adjusted – mean 4.7 6.9
3.8 6.5
5.3 7.0
5.0 6.9
5.3 7.2
5.2 6.8
4.3 6.2
5.2 6.6
5.1 7.3 Charlson index, unadjusted – mean 2.5 4.2
2.2 3.9
2.5 4.1
2.4 4.2
2.8 4.5
2.5 4.0
2.3 3.9
2.5 3.9
2.7 4.7
GP contacts in previous year – mean 6.5 10.9
4.9 9.2
6.9 10.3
6.6 10.6
8.7 12.4
7.0 10.2
7.0 9.9
9.0 13.7
8.8 14.0 Total observation time – years 610,856 28,722 198,581 5,211 65,183 4,972 61,308 4,178 13,171 940 32,675 2,685 25,343 1,451 1,484 255 1,502 272
![Page 13: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/13.jpg)
Incident cancers by DM treatment
Diabetes by treatment in the first three months following cancer diagnosis
All non-diabetes
All type 2 diabetes Met mono Sulf mono Insulin mono Met + Sulf Met + Insulin
Patients – n; % 140,141
9,890
1,635 16.5
1,844 18.6
753 7.6
1,295 13.1
320 3.2
Age – years (mean; sd) 65.7 15.0
71.4 9.7
70.2 9.8
73.6 9.3
70.2 9.3
71.7 9.0
67.4 9.0
Sex – % women 53.3
41.0
44.1
40.3
41.3
39.1
43.7 Smoking – % ever smoked 42.4
52.1
53.8
47.8
54.2
51.5
58.1
Diabetes duration – years (mean; median) n/a n/a
10.4 8.9
8.1 6.8
9.9 8.7
15.3 14.3
12.2 10.8
15.5 14.4
BMI males – kg/m2 (mean; sd) 26.0 3.7
28.6 4.3
29.8 4.3
27.3 3.9
28.2 4.4
28.7 4.3
30.2 4.2
BMI females – kg/m2 (mean; sd) 25.8 4.8
30.4 5.9
32.1 5.6
28.3 5.3
29.9 5.9
30.6 5.6
33.6 5.9
Systolic blood pressure – mmHg (mean; sd) 139.5 20.2
139.0 19.5
137.7 18.2
141.4 21.4
139.6 19.9
139.5 18.2
138 17.9
Total cholesterol – mmol/l (mean; sd) 5.0 1.2
4.4 1.1
4.3 1.1
4.5 1.2
4.3 1.1
4.3 1.1
4.1 1.0
HbA1c in year prior – % (mean; sd) 5.8 0.9
7.4 1.5
7.1 1.3
7.4 1.6
8.3 1.6
7.7 1.5
8.3 1.5
Prior vascular disease – % Large vessel disease 13.9
30.7
27.4
32.7
39.6
31.0
35.9
Eye problems (some) 1.3
14.4
10.9
11.0
30.5
16.7
25.6 Eye problems (severe visual loss/blindness) 1.8
3.3
2.0
4.2
4.9
3.0
5.6
No renal disease 99.1
92.9
94.4
92.6
88.4
93.9
91.6 Mild renal disease 0.0
4.6
4.8
4.0
6.2
4.9
7.5
Moderate/severe renal disease 0.9
2.5
0.8
3.4
5.3
1.2
0.9 General morbidity:
Charlson index,adjusted (mean; sd) 4.7 1.8
6.9 1.8
6.5 1.7
7.1 1.9
7.4 2.0
6.9 1.7
6.8 1.8
Charlson index, unadjusted (mean; sd) 2.5 0.9
4.2 1.4
3.9 1.2
4.2 1.5
4.9 1.7
4.2 1.3
4.5 1.5
GP contacts in previous year (mean; median) 6.5 5
10.9 9
10.6 9
10.2 8
13.4 10
10.7 9
13.4 11
Total observation time – years 610,856
28,722
4,564
5,754
2,054
3,950
690
Cancers – n; %
Breast 30,901 22.0
1,286 13.0
276 16.9
233 12.6
87 11.6
184 14.2
51 15.9
Prostate 16,872 12.0
1,475 14.9
274 16.7
259 14.0
89 11.8
234 18.1
48 15.0
Colorectal 15,617 11.1 1,363 13.8 213 13.0 249 13.5 97 12.9 181 14.0 43 13.4
![Page 14: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/14.jpg)
Mean survival by Ca. site (years)
17.4
7.5
26.9
11.0
18.2
8.8
14.2
7.7
13.6
7.9
10.5
8.4
3.3 3.2 2.6 2.61.7 1.4
0
5
10
15
20
25
30N
on-d
iabe
tes
Type
2 d
iabe
tes
Non
-dia
bete
s
Type
2 d
iabe
tes
Non
-dia
bete
s
Type
2 d
iabe
tes
Non
-dia
bete
s
Type
2 d
iabe
tes
Non
-dia
bete
s
Type
2 d
iabe
tes
Non
-dia
bete
s
Type
2 d
iabe
tes
Non
-dia
bete
s
Type
2 d
iabe
tes
Non
-dia
bete
s
Type
2 d
iabe
tes
Non
-dia
bete
s
Type
2 d
iabe
tes
All cancers Breast Ovarian & Endometrium
Colorectal Bladder Prostate Liver Lung Pancreas
![Page 15: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/15.jpg)
Δ mean survival by Ca. site (years)
9.9
15.9
9.4
6.45.7
2.1
0.1 0.1 0.30
2
4
6
8
10
12
14
16
18
All cancers Breast Ovarian & Endometrium
Colorectal Bladder Prostate Liver Lung Pancreas
![Page 16: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/16.jpg)
Cumulative mortality (crude)
DM
Non-DM
![Page 17: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/17.jpg)
Cumulative mortality (adjusted)
DM
Non-DM
Adjusted: age, sex, smoking, morbidity
![Page 18: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/18.jpg)
HR DM vs-N-DM (Cox)
Model # Model specification HR 95% CI p-value
Model 1 Age at Ca. diagnosis 1.067 1.024 1.113 0.00229
Model 2 Model 1, plus sex 1.040 0.997 1.084 0.06579
Model 3 Model 2, plus smoking status 1.129 1.082 1.176 0.00000
Model 4 Model 3, plus baseline morbidity* 0.969 0.928 1.011 0.14448
Model 5 Model 4, plus cancer site 0.904 0.860 0.951 0.00009
Model 6 Model 5, plus year of Ca. Diagnosis** 0.890 0.843 0.939 0.00002
Model 7 Model 6, plus no post-Ca. exposure to metformin 1.167 1.076 1.266 0.00018
Key: *, number of GP contacts in the year prior; **, after 1994 only
![Page 19: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/19.jpg)
adjHR: DM vs N-DM (=1) by treatment
1.121.10
0.94
0.87
0.79
0.75
0.80
0.85
0.90
0.95
1.00
1.05
1.10
1.15
Sulfonylurea monotherapy
Insulin monotherpy
Met+Insulin combination
Met+Sulf combination
Metfromin monotherapy
![Page 20: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/20.jpg)
Cum-mortality: ± metformin (adjusted)
Met-
Met+
Met-
Met+
Exposed in first 3 monthsExposed anytime aft Ca. diagHR=0.83; 0.78-0.89; p<0.00001HR=0.72; 0.68-0.76; p<0.00001
![Page 21: Introduction to UK GO data GPRD: General Practice Research Database THIN: Health Improvement Network Some new data too](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649d625503460f94a43d61/html5/thumbnails/21.jpg)
Cancer site Cases Events HR p-value Cases Events HR p-value
All cancers 130,270 51,468 0.975 0.918 1.037 0.42163 127,869 50,328 0.835 0.784 0.888 0.00000
Breast 31,720 6,459 1.125 0.918 1.379 0.25766 31,365 6,378 0.997 0.809 1.229 0.97808
Prostate 17,762 5,943 1.147 0.978 1.345 0.09195 17,426 5,834 1.034 0.877 1.218 0.69206
Colorectal 16,368 6,905 0.900 0.761 1.065 0.22008 16,043 6,766 0.783 0.659 0.931 0.00564
Lung 13,083 9,798 0.695 0.597 0.808 0.00000 12,697 9,499 0.626 0.537 0.730 0.00000
Bladder 7,497 2,893 1.107 0.876 1.399 0.39296 7,356 2,823 0.958 0.756 1.216 0.72644
Ovarian and Endomeytrial 5,882 2,165 0.585 0.419 0.817 0.00168 5,747 2,103 0.550 0.390 0.777 0.00069
Pancreas 2,314 1,788 0.712 0.550 0.923 0.01022 2,250 1,737 0.655 0.503 0.853 0.00169
Liver 1,452 1,010 0.705 0.503 0.987 0.04184 1,411 978 0.673 0.475 0.955 0.02636
All cancers 130,270 51,468 0.834 0.787 0.885 0.00000 127,869 50,328 0.717 0.675 0.761 0.00000
Breast 31,720 6,459 1.063 0.891 1.268 0.49931 31,365 6,378 0.927 0.773 1.112 0.41267
Prostate 17,762 5,943 1.061 0.920 1.225 0.41555 17,426 5,834 0.960 0.829 1.112 0.58756
Colorectal 16,368 6,905 0.804 0.688 0.940 0.00611 16,043 6,766 0.709 0.604 0.831 0.00002
Lung 13,083 9,798 0.626 0.533 0.735 0.00000 12,697 9,499 0.562 0.477 0.663 0.00000
Bladder 7,497 2,893 0.929 0.748 1.153 0.50314 7,356 2,823 0.818 0.655 1.020 0.07486
Ovarian and Endomeytrial 5,882 2,165 0.607 0.453 0.813 0.00083 5,747 2,103 0.579 0.429 0.781 0.00035
Pancreas 2,314 1,788 0.626 0.466 0.840 0.00180 2,250 1,737 0.582 0.432 0.785 0.00038
Liver 1,452 1,010 0.569 0.398 0.813 0.00195 1,411 978 0.557 0.385 0.807 0.00198
Model A = age + sex + smoking + metformin parameter; Model B = age + sex + smoking + baseline morbidity + metformin parameter
Met+ vs Met- (<3 mths) Model A
Met+ vs Met- (>3 mths) Model A
95% CI
Met+ vs Met- (<3 mths) Model B
Met+ vs Met- (>3 mths) Model B
95% CI